Galecto, Inc. GLTO 深 沪
已收盘 02-06 16:00:00 美东时间
25.26
+2.630
+11.62%
华盛通- 最 高26.10
- 今 开23.10
- 成交量 4.89万股
- 最 低 23.10
- 昨 收 22.63
- 总市值 4041.53万
- 52周最高 38.3251
- 市盈率 静 --
- 换手率 3.06%
- 52周最低 2.01
- 委 比 -96.51%
- 总股本 160.00万
- 历史最高 449.75
- 量 比 1.26
- 振 幅 13.26%
- 历史最低 2.01
- 每 手 1
- 风险率 9.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Leerink Partners Initiates Coverage On Galecto with Outperform Rating, Announces Price Target of $46
Leerink Partners analyst Andrew Berens initiates coverage on Galecto (NASDAQ:GLTO) with a Outperform rating and announces Price Target of $46.
01-08 00:25
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
Guggenheim Maintains Buy on Galecto, Raises Price Target to $36
Guggenheim analyst Brad Canino maintains Galecto (NASDAQ:GLTO) with a Buy and raises the price target from $32 to $36.
2025-12-08 21:35
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
Guggenheim Initiates Coverage On Galecto with Buy Rating, Announces Price Target of $32
Guggenheim analyst Brad Canino initiates coverage on Galecto (NASDAQ:GLTO) with a Buy rating and announces Price Target of $32.
2025-12-01 20:49
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers MSP Recovery (NASDAQ:MSPR) shares rose 93.0% to $0.61 during Tuesday's...
2025-11-11 20:07
Market-Moving News for November 10th
PLUG: 12% | Plug Power shares are trading higher after signing a non-binding LOI to monetize electricity rights in New York and another location and partner with a U.S. data center developer. GLTO: 400% |
2025-11-10 20:28
Galecto Acquires Damora Therapeutics, Pays ~$284.9M In Form Of Private Placement Of Series C Non-Voting Convertible Preferred Stock
Galecto, Inc. ("Galecto") today announced the completion of the acquisition of Damora Therapeutics, Inc. ("Damora"), a privately held biotechnology company advancing a pipeline of antibody therapeutics aimed at
2025-11-10 20:04
Galecto Reports Third Quarter 2025 Operating and Financial Results
Galecto, Inc. announced its third-quarter 2025 results, highlighting positive FDA feedback on GB3226, a dual inhibitor targeting AML, with plans to submit an IND in early 2026. Cash reserves stood at $7.6 million, sufficient for near-term GB3226 development. R&D expenses rose by $0.3 million, while G&A costs fell by $1.0 million. The company reported a net loss of $3.1 million, narrowed from $3.9 million the prior year. Galecto emphasizes its com...
2025-11-06 21:30
